Johnson & Johnson forecasts 2026 profit above Wall Street estimates

By Michael Erman

Jan 21 (Reuters) - Johnson & Johnson connected Wednesday forecast 2026 income and nett up of Wall Street estimates, adjacent erstwhile including a deed of "hundreds of millions of dollars" from ​the cause pricing woody it signed with the Trump medication earlier this month.

J&J is 1 of ‌16 large pharmaceutical companies that person reached agreements to little U.S. cause prices successful speech for exemptions from Trump-imposed tariffs.

"We can't disclose ‌specific details, but it's hundreds of millions of dollars," Chief Financial Officer Joseph Wolk said successful an interview. "It's a recognition to the squad present that we were capable to surpass what (analyst) expectations are for 2026 by a beauteous sizable magnitude portion digesting that impact."

The institution forecast 2026 operational income of $99.5 cardinal to $100.5 billion, exceeding analysts' estimates ⁠of $98.9 billion, according to LSEG data.

J&J expects ‌full-year 2026 nett coming successful astatine $11.43 to $11.63 per share. Analysts person forecast net of $11.45 per share.

Despite the upbeat forecast, shares of the institution fell 2.7% successful premarket trading. ‍They gained astir 43% successful 2025.

The results onshore a time aft a court-appointed peculiar maestro recommended that adept grounds linking the company's talc products to ovarian crab beryllium allowed successful court.

J&J has been warring claims implicit its talc products successful ​both national and authorities tribunal for years, and has said its products are harmless and bash not ‌cause cancer.

J&J besides reported fourth-quarter 2025 nett up of expectations, buoyed by beardown income of humor crab therapy Darzalex, coagulated maturation successful psoriasis cause Tremfya and resilience successful its aesculapian devices business.

The upbeat show comes arsenic the institution faces aggregate challenges, including tariff uncertainty connected its aesculapian devices portion and rising contention for its blockbuster psoriasis cause Stelara from biosimilars. Stelara income declined much than analysts had forecast.

"How bully is it that ⁠Stelara was down truthful overmuch - possibly adjacent much than analysts ​thought - and we inactive proceed to grow?" Wolk said.

"If you conscionable ​take Stelara retired of that mix, that portfolio is increasing 14%, 15%. Those are the products that we're going to trust connected for the adjacent mates years and the ‍balance of this decade."

On an ⁠adjusted basis, the healthcare conglomerate earned $6 billion, oregon $2.46 per share, for the quarter. Analysts were expecting a nett of $2.44 per share.

Quarterly gross of $24.56 cardinal besides topped Wall Street expectations of $24.16 billion.